Peter MacCallum Cancer Centre
HaemaLogix, Peter MacCallum Cancer Center Team Up on Myeloma CAR T-Cell Therapy Trial
The Australian drugmaker and cancer center will conduct a Phase I trial of HaemaLogix's KMA.CAR-T in kappa myeloma antigen-expressing myeloma patients.
Researchers in Australia, Germany, and the US are in the early stages of developing a prostate cancer radiopharmaceutical they say could be manufactured in-house via a desktop machine.
PSMA, Tumor Metabolic Volume May Help Refine Pluvicto Use in Prostate Cancer, Study Suggests
Premium
An Australian study explored the predictive and prognostic ability of two PET imaging-based biomarkers to guide treatment with Novartis' radioligand therapy.
WEHI Launches Project to Improve Genomic Data Interpretation, Precision Cancer Care in Australia
The institute and its research partners aim to develop a tool that bridges disconnected genomic data sets and translate the data to improve understanding of blood, breast, and ovarian cancers.
Isotopia, Peter MacCallum Cancer Centre Partner on Prostate Cancer Radiopharmaceutical Study
The partners plan to evaluate a PSMA-targeted radiopharmaceutical for advanced prostate cancer using terbium-161, which may be superior to lutetium-177.